Skip to main content
SpringerLink
Log in
Book cover

Somatostatin pp 215–231Cite as

Somatostatin Analogs in the Treatment of Pituitary Tumors

  • Chapter

  • 159 Accesses

Part of the book series: Endocrine Updates ((ENDO,volume 24))

Abstract

Recently the medical approach to patients with secreting and nonsecreting pituitary adenomas has received great impulse thanks to the availability of new somatostatin analogs provided with slow release, such as lanreotide (LAN) and octreotide-LAR (OCT-LAR). In acromegaly, disease control (GH≤2.5μg/l) as fasting value or ≤1μg/l after glucose load, together with age-normalized IGFI) is achievable in more than half patients under treatment with LAN and OCTLAR. Improvement of cardiomyopathy, sleep apnea and arthropathy has been reported during treatment with these somatostatin analogs. LAN displayed beneficial effects also in TSH-secreting adenomas, while the results of treatment with these peptides in patients with clinically nonfunctioning adenomas are still rather limited and controversial.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Nabarro J.D.N. Acromegaly. Clin Endocrinol 1987; 26: 481–512.

    CAS  Google Scholar 

  2. Rajasoorya C., Holdaway I.M., Wrightson P., Scott D.J., Ibbertson H.K. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol 1994; 41: 95–102.

    CAS  Google Scholar 

  3. Melmed S., Ho K., Klibanski A., Reichlin S., Thorner M.O. Recent advances in pathogenesis, diagnosis and management of acromegaly. J Clin Endocrinol Metab 1995; 80:3395–3402.

    Article  CAS  PubMed  Google Scholar 

  4. Colao A., Merola B., Ferone D., Lombardi G. Acromegaly. J Clin Endocrinol Metab 1997; 82:2777–2781.

    CAS  PubMed  Google Scholar 

  5. Colao A., Lombardi G. GH and PRL excess. Lancet 1998; 352:1455–1461.

    Article  CAS  PubMed  Google Scholar 

  6. Orme S.M., McNally R.J., Cartwright R.A., Belchetz P.E. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 1998; 83: 2730–2734.

    Article  CAS  PubMed  Google Scholar 

  7. Giustina A., Barkan A., Casanueva F.F., Cavagnini F., Frohman L., Ho K., Veldhuis J., Wass J., Von Werder K., Melmed S. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 2000; 85:526–529.

    Article  CAS  PubMed  Google Scholar 

  8. Melmed S., Jackson I., Kleinberg D., Klibanski A. Current treatment guidelines for acromegaly. J Clin Endocrinol Metab 1998; 83:2646–2652.

    CAS  PubMed  Google Scholar 

  9. Ferone D., Colao A., van der Lely A-J., Lamberts S.W.J. Pharmacotherapy or Surgery as Primary Treatment for Acromegaly? Drugs 2000; 17: 81–92.

    CAS  Google Scholar 

  10. Newman C.B., Melmed S., George A., Torigian D., Duhaney M., Snyder P., Young W., Klibanski A., Molitch M.E., Gagel R., Sheeler L., Cook D., Malarkey W., Jackson I., Vance M.L., Barkan A., Frohman L., Kleinberg D.L. Octreotide as primary therapy for acromegaly. J Clin Endocrinol Metab 1998; 83: 3034–3040.

    Article  CAS  PubMed  Google Scholar 

  11. Freda P.U., Wardlaw S.L. Primary therapy of acromegaly. J Clin Endocrinol Metab 1998; 83:3031–3033

    CAS  PubMed  Google Scholar 

  12. Colao A., Ferone D., Marzullo P., Di Samo A., Cerbone G., Sarnacchiaro F., Cirillo S., Merola B., Lombardi G. Effect of different dopaminergic agents in the treatment of acromegaly. J Clin Endocrinol Metab 1997; 82:518–523.

    CAS  PubMed  Google Scholar 

  13. Abs R., Versholst J., Maiter D., Van Acker K., Nobels F., Coolens J.L., Mahler C., Beckers A. Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab 1998; 83:374–378.

    Article  CAS  PubMed  Google Scholar 

  14. Cozzi R., Attanasio R., Barausse M., Dallabonzana D., Orlandi P., Da Re N., Branca V., Oppizzi G., Gelli D. Cabergoline in acromegaly: a renewed role for dopamine agonist treatment? Eur J Endocrinol 1998; 139:516–521.

    Article  CAS  PubMed  Google Scholar 

  15. Lamberts S.W.J., van der Lely A-J., de Herder W.W., Hofland L.J. Octreotide. N Engl J Med 1996; 334:246–254.

    Article  CAS  PubMed  Google Scholar 

  16. Lamberts S.W.J., Uitterlinden P., Verschoor L., van Dongen K.J., del Pozo E. Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995. N Engl J Med 1985; 313:1576–1580.

    CAS  PubMed  Google Scholar 

  17. Barkan A. Acromegalic arthropathy and sleep apnea. J Endocrinol 1997; 155:841–44.

    Google Scholar 

  18. Thuesen L., Christensen S.E., Weeke J., Ørskov H., Henningsen P. The cardiovascular effects of Octreotide treatment in acromegaly: an echocardiographic study. Clin Endocrinol 1989; 30: 619–625.

    CAS  Google Scholar 

  19. Pereira J.L., Rodriguez-Puras M.J., Leal-Cerro A., Martinez A., Garcia-Luna P.P., Gavilan I., Pumar A., Astorga R. Acromegalic cardiopathy improves after treatment with increasing doses of Octreotide. J Endocrinol Invest 1991; 14: 17–23

    CAS  PubMed  Google Scholar 

  20. Lim M.J., Barkan A.L., Buda A.J. Rapid reduction of left ventricular hypertrophy in acromegaly after suppression of growth hormone hypersecretion. Ann Intern Med 1992; 117:719–726.

    CAS  PubMed  Google Scholar 

  21. Merola B., Cittadini A., Colao A., Ferone D., Fazio S., Sabatini D., Biondi B., Saccà L., Lombardi G. Chronic treatment with the somatostatin analog Octreotide improves cardiac abnormalities in acromegaly. J Clin Endocrinol Metab 1993; 77: 790–3.

    CAS  PubMed  Google Scholar 

  22. Chanson P., Timsit J., Masquet C., Warnet A., Guillausseau P.J., Birman P., Harris A.G., Lubetzki J. Cardiovascular effects of the somatostatin analog octreotide in acromegaly. Ann Intern Med 1990; 113: 921–925.

    CAS  PubMed  Google Scholar 

  23. Colao A., Cuocolo A., Marzullo P., Nicolai E., Ferone D., Florimonte L., Salvatore M., Lombardi G. Effects of one-year treatment with octreotide on cardiac performance in patients with acromegaly. J Clin Endocrinol Metab 1999; 84: 17–23.

    CAS  PubMed  Google Scholar 

  24. Colao A., Cuocolo A., Marzullo P., Nicolai E., Ferone D., Della Morte A.M., Pivonello R., Salvatore M., Lombardi G. Is the acromegalic cardiomyopathy reversible? Effect of 5 year normalization of growth hormone and insulin-like growth factor-I levels on cardiac performance. J Clin Endocrinol Metab 2001; 86: April

    Google Scholar 

  25. Waine H., Bennet G.A., Bauer, W. Joint disease associated with acromegaly. Am J Med Sci 1945; 209: 671–678.

    Google Scholar 

  26. Kellgren J.H., Ball, J., Tutton, G.K. The articular and other limb changes in acromegaly. Q J Med 1952; 21: 405–423.

    CAS  PubMed  Google Scholar 

  27. Bluestone R., Bywaters E., Hartog M., Holt P.J.L., Hyde S. Acromegalic arthropathy. Ann Rheum Dis 1971; 30: 43–258.

    Google Scholar 

  28. Colao A., Marzullo P., Vallone G., Marinò V., Annecchino M., Ferone D., De Brasi D., Scarpa R., Oriente P., Lombardi G. Reversibility of joint thickening in acromegalic patients: an ultrasonography study. J Clin Endocrinol Metab 1998; 83:2121–2125

    CAS  PubMed  Google Scholar 

  29. Colao A., Marzullo P., Spiezia S., Ferone D., Giaccio A., Cerbone G., Pivonello R., Di Somma C., Lombardi G. Effect of growth hormone (GH) and insulin-like growth factor-I on prostate diseases: an ultrasonographic and endocrine study in acromegaly, GH-deficiency and healthy subjects. J Clin Endocrinol Metab 1999; 84: 1986–1991.

    CAS  PubMed  Google Scholar 

  30. Colao A., Marzullo P., Ferone D., Spiezia S., Cerbone G., Marinò V., Di Sarno A., Lombardi G. Prostatic hyperplasia: an unknown feature of acromegaly. J Clin Endocrinol Metab 1998; 83:2606–2607.

    CAS  Google Scholar 

  31. Morange I., de Boisvilliers F., Chanson P., Lucas B., DeWailly D., Catus F., Thomas F., and Jaquet P.: Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide. J Clin Endocrinol Metab 1994; 79:145–151.

    Article  CAS  PubMed  Google Scholar 

  32. Giusti M., Gussoni G., Cuttica C.M., Giordano G., and the Italian Multicenter Slow Release Lanreotide Study Group: Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly; six month report on an Italian multicenter study. J Clin Endocrinol Metab 1996; 81:2089–2097.

    Article  CAS  PubMed  Google Scholar 

  33. Colao A., Marzullo P., Ferone D., Marinò V., Pivonello R., Di Somma C., Di Sarno A., Giaccio A., Lombardi G.: Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly. J Endocrinol Invest 1999; 22: 40–47.

    CAS  PubMed  Google Scholar 

  34. Suliman M., Jenkins R., Ross R., Powell T., Battersby R., Cullen D.R. Long-term treatment of acromegaly with the somatostatin analogue SR-lanreotide. J Endocrinol Invest 1999 22: 409–418.

    CAS  PubMed  Google Scholar 

  35. Cannavò S., Squadrito S., Curto L., Almoto B., Vieni A., Trimarchi F. Results of a two year treatment with slow-release lanreotide. Horm Metab Res 2000; 32: 224–9.

    PubMed  Google Scholar 

  36. Verhelst J.A., Pedroncelli A.M., Abs R., Montini M., Vanderweghe M.V., Albani G., Mailer D., Pagani M.D., Legros J.J., Gianola D., Bex M., Pop Mockel J., Pagani G. Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients. Eur J Endocrinol 2000; 143: 577–584.

    Article  CAS  PubMed  Google Scholar 

  37. Caron P., Morange-Ramos I., Cogne M., and Jaquet P. Three year follow up of acromegalic patients treated with intramuscular slow-release lanreotide. J Clin Endocrinol Metab 1997; 82:18–22

    CAS  PubMed  Google Scholar 

  38. Baldelli R., Colao A., Razzore P., Jaffrain-Rea M-L., Marzullo P., Ciccarelli E., Ferretti E., Ferone D., Gaia D., Camanni F., Lombardi G., Tamburrano G. Two-year follow-up of acromegalic patients treated with SR-lanreotide 30 mg. J Clin Endocrinol Metab 2000; 85: 4099–4103.

    Article  CAS  PubMed  Google Scholar 

  39. Baldelli R., Ferretti E., Jaffrain-Rea M.L., Iacobellis G., Minniti G., Caracciolo B., Moroni C., Cassone R., Gulino A., Tamburrano G. Cardiac effects of slow-release lanreotide, a slow-release somatostatin analog, in acromegalic patients. J Clin Endocrinol Metab 1999; 84:575–532.

    Article  Google Scholar 

  40. Hradec J., Kral J., Janota T., Krsek M., Hana V., Marek J., Malik M. Regression of acromegalic left ventricular hypertrophy after lanreotide (a slow release somatostatin analog). Am J Cardiol 1999; 83: 1506–1509.

    Article  CAS  PubMed  Google Scholar 

  41. Colao A., Marzullo P., Vallone G., Giaccio A., Ferone D., Scarpa R., Rossi E., Smaltino F., Lombardi G. Ultrasonographic evidence of joint thickening reversibility in acromegalic patients treated with lanreotide for 12 months. Clin Endocrinol 1999; 51:611–618.

    Article  CAS  Google Scholar 

  42. Colao A., Marzullo P., Spiezia S., Giaccio A., Ferone D., Cerbone G., Di Sarno A., Lombardi G. Effect of two years of growth hormone-insulin-like growth factor-I suppression on prostate diseases in acromegalic patients. J Clin Endocrinol Metab 2000; 85: 3754–3761.

    CAS  PubMed  Google Scholar 

  43. Manelli F., Desenzani P., Boni E., Bugari G., Negrini F., Romanelli G., Grassi V., Giustina A. Cardiovascular effects of a single slow release lanreotide injection in patients with acromegaly and left ventricular hypertrophy. Pituitary 1999; 2:205–10.

    Article  CAS  PubMed  Google Scholar 

  44. Manelli F., Bossoni S., Burattin A., Doga M., Solerte S.B., Romanelli G., Giustina A. Exercise-induced microalbuminuria in patients with active acromegaly: acute effects of slow-release lanreotide, a long-acting somatostatin analog. Metabolism 2000; 49:634–9.

    Article  CAS  PubMed  Google Scholar 

  45. Caron P., Beckers A., Cullen D.R., Goth M.I., Gutt B., Laurberg P., Pico A.M., Valimaki M., Zgliczynski W. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. J Clin Endocrinol Metab. 2002; 87:99–104.

    Article  CAS  PubMed  Google Scholar 

  46. Gillis J.C., Noble S., Goa K.L. Octreotide long-acting release (LAR). A review of its phamacological properties and therapeutic use in the management of acromegaly. Drugs 1997;53:681–699.

    CAS  PubMed  Google Scholar 

  47. Stewart P.M., Kane K.F., Stewart S.E., Lancranjan I., Sheppard M.C. Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly. J Clin Endocrinol Metab 1995; 80:3267–3272.

    CAS  PubMed  Google Scholar 

  48. Flogstad A., Halse J., Bakke S., Lancranjan I., Marbach P., Bruns C., Jervell J. Sandostatin LAR in acromegalic patients: long term treatment. J Clin Endocrinol Metab 1997; 82:23–28

    Article  CAS  PubMed  Google Scholar 

  49. Lancranjan I., Atkinson A.B. and the Sandostatin® LAR® group. Results of a European multicenter study with Sandostatin® LAR® in acromegalic patients. Pituitary 1999; 1: 105–114.

    Article  CAS  PubMed  Google Scholar 

  50. Colao A., Ferone D., Marzullo P., Cappabianca P., Cirillo S., Boerlin V., Lancranjan I., Lombardi G. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab 2001; 86: in press

    Google Scholar 

  51. Bevan J.S., Atkin S.L., Atkinson A.B., Bouloux P.M., Hanna F., Harris P.E., James R.A., McConnell M., Roberts G.A., Scanlon M.F., Stewart P.M., Teasdale E., Turner H.E., Wass J.A., Wardlaw J.M. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J Clin Endocrinol Metab. 2002; 87:4554–63.

    Article  CAS  PubMed  Google Scholar 

  52. Colao A., Marzullo P., Ferone D., Spinelli L., Cuocolo A., Bonaduce D., Salvatore M., Boerlin V., Lancranjan I., Lombardi G. Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR® in acromegaly. J Clin Endocrinol Metab 2000; 86: 3132–3140.

    Google Scholar 

  53. Colao A., Marzullo P., Cuocolo A., Spinelli L., Pivonello R., Bonaduce D., Salvatore M., Lombardi G. Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide. Clin Endocrinol (Oxf). 2003; 58:169–76.

    Article  CAS  Google Scholar 

  54. Moschetta A., Stolk M.F., Rehfeld J.F., Portincasa P., Slee P.H., Koppeschaar H.P., Van Erpecum K.J., Vanberge-Henegouwen G.P. Severe impairment of postprandial cholecystokinin release and gall-bladder emptying and high risk of gallstone formation in acromegalic patients during Sandostatin LAR. Aliment Pharmacol Ther 2001; 15:181–185.

    Article  CAS  PubMed  Google Scholar 

  55. Kendall-Taylor P., Miller M., Gebbie J., Turner S., al-Maskari M. Long-acting octreotide LAR compared with lanreotide SR in the treatment of acromegaly. Pituitary 2000; 3:61–5.

    Article  CAS  PubMed  Google Scholar 

  56. Chanson P., Boerlin V., Ajzenberg C., Bachelot Y., Benito P., Bringer J., Caron P., Charbonnel B., Cortet C., Delemer B., Escobar-Jimenez F., Foubert L., Gaztambide S., Jockenhoevel F., Kuhn J.M., Leclere J., Lorcy Y., Perlemuter L., Prestele H., Roger P., Rohmer V., Santen R., Sassolas G., Scherbaum W.A., Schopohl J., Torres E. Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly. Clin Endocrinol 2000; 53:577–86

    Article  CAS  Google Scholar 

  57. Marzullo P., Ferone D., Di Somma C., Pivonello R., Filippella M., Lombardi G., Colao A Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant acromegalic patients. Pituitary 1999; 1:115–20

    Article  CAS  PubMed  Google Scholar 

  58. Rocheville M., Lange D.C., Kumar U., Patel S.C., Patel R.C., Patel Y.C. Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 2000; 288:154–157.

    Article  CAS  PubMed  Google Scholar 

  59. Spinas G.A., Zapf J., Landolt A.M., Stuckmann G., Froesch E.R. Pre-operative treatment of 5 acromegalics with a somatostatin analogue: endocrine and clinical observations. Acta Endocrinol 1987; 114:249–256.

    CAS  PubMed  Google Scholar 

  60. Barkan A., Lloyd R.V., Chandler W.F. Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201-995: shrinkage of invasive pituitary macroadenomas and improved surgical remission rate. J Clin Endocrinol Metab 1988; 67:1040–1048.

    CAS  PubMed  Google Scholar 

  61. Stevenaert A., Harris A.G., Kovacs K., Beckers A. Presurgical octreotide treatment in acromegaly. Metabolism 1992; 41:51–58.

    Article  CAS  PubMed  Google Scholar 

  62. Lucas Morante T., Garcia Uria L., Estrada J., Saucedo G., Cabello A., Alcaniz. J., and Barcelo B. Treatment of invasive growth hormone pituitary adenomas with long-acting somatostatin analog SMS 210–995 before transsphenoidal surgery. J Neurosurg 1994; 81: 10–14.

    CAS  PubMed  Google Scholar 

  63. Waśko R., Ruchala M., Sawicka J., Kotwocka M., Liebert W., Sowiński J. Short-term pre-surgical treatment with somatostatin analogues, octreotide and lanreotide, in acromegaly. J Endocrinol Invest 2000; 23: 12–18.

    PubMed  Google Scholar 

  64. Plockinger U., Reichel M., Fett U., Saeger W., Quabbe H-J. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: Effects on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy. J Clin Endocrinol Metab 1994; 79:1416–1423.

    Article  CAS  PubMed  Google Scholar 

  65. Ezzat S., Horvath E., Harris A.G., Kovacs K. Morphological effects of octreotide on growth hormone-producing pituitary adenomas. J Clin Endocrinol Metab 1994; 79:113–118.

    Article  CAS  PubMed  Google Scholar 

  66. Biermasz N.R., van Dulken H., Roelfsema F. Direct postoperative and follow-up results of transsphenoidal surgery in 19 acromegalic patients pretreated with octreotide compared to those in untreated matched controls. J Clin Endocrinol Metab 1999; 84:3551–5

    Article  CAS  PubMed  Google Scholar 

  67. Colao A., Ferone D., Cappabianca P., de Caro M.L., Marzullo P., Monticelli A., Alfieri A., Merola B., Calì A., de Divitiis E., Lombardi G. Effect of octreotide pretreatment on surgical outcome in acromegaly. J Clin Endocrinol Metab 1997;82:3308–3314.

    CAS  PubMed  Google Scholar 

  68. Bates A., vant’Hoff W., Jones J., Clayton R. An audit of outcome of treatment in acromegaly. Q J Med 1993; 86;293–299.

    CAS  PubMed  Google Scholar 

  69. Jenkins P.J., Akker S., Chew S.L., Besser G.M., Monson J.P., Grossman A.B. Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration. Clin Endocrinol 2000 53:719–724

    Article  CAS  Google Scholar 

  70. Afargan M., Janson E.T., Gelerman G., Rosenfeld R., Ziv O., Karpov O., Wolf A., Bracha M., Shohat D., Liapakis G., Gilon C., Hoffman A., Stephensky D., Oberg K. Novel Long-Acting Somatostatin Analog with Endocrine Selectivity: Potent Suppression of Growth Hormone But Not of Insulin. Endocrinology 2001; 142:477–486

    Article  CAS  PubMed  Google Scholar 

  71. Trainer P.J., Drake W.M., Katznelson L., Freda P.U., Herman-Bonert V., van der Lely A-J., Dimaraki E.V., Stewart P.M., Friend K.E., Vance M.L., Besser G.M., Scarlett J. A., Thorner M.O., Parkinson C., Klibanski A., Powell J.S., Barkan A.L., Sheppard M.C., Malsonado M., Rose D.R., Clemmons D.R., Johannsson G., Bengtsson B.A., Stavrou S., Kleinberg D.L., Cook D.M., Phillips L.S., Bidlingmaicr M., Strasburgcr C.J., Hackett S., Zib K., Bennett W.F., and Davis R.J. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 2000; 342:1171–7

    Article  CAS  PubMed  Google Scholar 

  72. Herman-Bonert V.S., Zib K., Scarlett J. A., Melmed S. Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs. J Clin Endocrinol Metab 2000; 85:2958–61

    Article  CAS  PubMed  Google Scholar 

  73. Kaal A., Orskov H., Nielsen S., Pedroncelli A.M., Lancranjan I., Marbach P., Weeke J. Occurrence and effects of octreotide antibodies during nasal, subcutaneous and slow release intramuscular treatment. Eur J Endocrinol 2000; 143:353–61

    Article  CAS  PubMed  Google Scholar 

  74. Beck-Peccoz P., Brucker-Davis F., Persani L., Smallridge R.C., Weintraub B.D. Thyrotropin-secreting pituitary tumors. Endocr Rev 1996;17:610–638.

    Article  CAS  PubMed  Google Scholar 

  75. Brucker-Davis F., Oldfield E.H., Skarulis M.C., Doppman J.L., Weintraub B.D. Thyrotropin-secreting pituitary tumors: diagnostic criteria, thyroid hormone sensitivity, and treatment outcome in 25 patients followed at the National Institute of Health. J Clin Endocrinol Metab 1999; 84:476–486.

    Article  CAS  PubMed  Google Scholar 

  76. Smallridge R.C. Thyrotropin-secreting pituitary tumors. Endocrinol Metab. 1987; 16:765–791.

    CAS  Google Scholar 

  77. Mc Cutcheon I.E., Weintraub B.D., Oldfield E.H. Surgical treatment of thyrotropin secreting adenomas. J Neurosurg. 1990; 73:674–683.

    CAS  Google Scholar 

  78. Losa M., Giovanelli M., Persani L., Mortini P., Faglia G., Beck-Peccoz P. Criteria of cure and follow-up of central hyperthyroidism due to thyrotropin-secreting pituitary adenomas. J Clin Endocrinol Metab 1996; 81:3084–3090.

    Article  CAS  PubMed  Google Scholar 

  79. Chanson P., Weintraub B.D., Harris A.G. Treatment of TSH-secreting pituitary adenomas with octreotide: a follow-up of 52 patients. Ann Intern Med 1993; 119:236–240.

    CAS  PubMed  Google Scholar 

  80. Siler T.M., Yen S.S.C., Vale W., Guillemin R. Inhibition by somatostatin of the release of TSH induced in man by thyrotropin-releasing factor. J Clin Endocrinol Metab. 1974; 38:742–745.

    CAS  PubMed  Google Scholar 

  81. Weeke J., Hansen A.P., Lundaek K. Inhibition by somatostatin of basal levels of serum thyrotropin (TSH) in normal men. J Clin Endocrinol Metab. 1975; 41:168–171

    CAS  PubMed  Google Scholar 

  82. Reschini E., Giustina G., Cantalemessa L., Peracchi M. Hyperthyroidism with elevated plasma TSH levels and pituitary tumor: study with somatostatin. J Clin Endocrinol Metab. 1976; 46:924–927.

    Google Scholar 

  83. Losa M., Magnani P., Mortini P., Persani L., Acerno S., Giugni E., Songini C., Fazio F., Beck-Peccoz P., Giovanelli M. Indium-11l pentetreotide single-photon emission tomography in patients with TSH-secreting pituitary adenomas: correlation with the effect of a single administration of octreotide on serum TSH levels. Eur J Nucl Med 1997; 24:728–731.

    CAS  PubMed  Google Scholar 

  84. Christensen S.E., Weeke J., Kaal A., Harris A.G., Orskov H. SMS 201–995 and thyroid function in acromegaly: acute, intermediate and long-term effects. Horm Metab Res. 1992; 24:237–239.

    CAS  PubMed  Google Scholar 

  85. Beck-Peccoz P., Mariotti S., Guillausseau P.J. et al. Treatment of thyrotropin with the somatostatin analog SMS 201–295 J Clin Endocrinol Metab. 1989; 68:208–214.

    CAS  PubMed  Google Scholar 

  86. Chanson P., Warnet A. Treatment of thyroid-stimulating hormone-secreting adenomas with octreotide. Metabolism. 1992; 4:62–65.

    Google Scholar 

  87. Comi R.J., Gesundheit N., Murray L., Gorden P., Weintraub B.D. Response of thyrotropin-secreting pituitary adenomas to a long-acting somatostatin analogue. N Engl J Med. 1992; 317:12–17.

    Google Scholar 

  88. Gesundheit N, Petrik PA, Nissim M, et al. Thyrotropin-secreting pituitary adenomas: clinical and biochemical heterogeneity. Ann Intern Med. 1989; 111:827–835

    CAS  PubMed  Google Scholar 

  89. Guillausseau PJ, Chanson P, Timsit J, et al. Visual improvement with SMS 201-995 in a patient with a thyrotropin-secreting adenoma. N Engl J Med. 1987; 317:53–54.

    CAS  PubMed  Google Scholar 

  90. Warnet A, Lajeunie E, Gelbert F, et al. Shrinkage of a primary thyrotropin-secreting pituitary adenoma treated with the long-acting somatostatin analogue octreotide (SMS 201-995). Acta Endocrinol (Copenh). 1991; 124:487–491

    CAS  Google Scholar 

  91. Wemeau L, Dewailly D, Leroy R, et al. Long term treatment with a somatostatin analog SMS 201-995 in a patient with a thyrotropin and growth hormone-secreting pituitary adenoma. J Clin Endocrinol Metab. 1988; 66:636–639.

    CAS  PubMed  Google Scholar 

  92. Gancel A., Vuillermet P., Legrand A., Catus F., Thomas F., Kuhn J.M. Effects of a slow-release formulation of the new somatostatin analogue lanreotide in TSH-secreting pituitary adenomas. Clin Endocrinol 1994; 40:421–428.

    CAS  Google Scholar 

  93. Kuhn J.M., Arlot S., Lefebvre H., Caron P., Cortet-Rudelli C., Archambaud F., Chanson P., Tabarin A., Goth M.I., Blumberg J., Catus F., Ispas S., Beck-Peccoz P. Evaluation of the Treatment of Thyrotropin-Secreting Pituitary Adenomas with a Slow Release Formulation of the Somatostatin Analog Lanreotide J Clin Endocrinol Metab 2000; 851487–1491

    Article  CAS  PubMed  Google Scholar 

  94. Katnelson L., Alexander J.M., Klibanski A. Clinically nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 1993; 76:1089–1094.

    Google Scholar 

  95. Freda P.U., Wardlaw S.L. Diagnosis and treatment of pituitary tumors. J Clin Endocrinol Metab 1999; 84:3859–3866.

    Article  CAS  PubMed  Google Scholar 

  96. Ikuyama S., Nawata H., Kato K., Karashima T., Ibayashi H., Nakagaki H. Specific somatostatin receptors on human pituitary adenoma cell membranes. J Clin Endocrinol Metab 1985; 61: 98–103

    Google Scholar 

  97. Reubi J.C., Heitz P.U., Landolt A.M. Visualization of somatostatin receptors and correlation with immunoreactive growth hormone and prolactin in human pituitary adenomas: evidence for different tumor subclasses. J Clin Endocrinol Metab 1987; 65: 65–73.

    CAS  PubMed  Google Scholar 

  98. Greenman Y., Melmed S. Heterogeneous expression of two somatostatin receptor subtypes in pituitary tumors. J Clin Endocrinol Metab 1994; 78: 398–403.

    Article  CAS  PubMed  Google Scholar 

  99. Faglia G., Bazzoni N., Spada A., Arosio M., Ambrosi B., Spinelli F., Sara R., Bonino C., Lunghi F. In vivo detection of somatostatin receptors in patients with functionless pituitary adenomas by means of a radio-iodinated analog of somatostatin [(123 I)SDZ204-090]. J Clin Endocrinol Metab 1991;73:850–856.

    CAS  PubMed  Google Scholar 

  100. Plockinger U, Reichel M., Fett U., Saeger W., Quabbe H.J. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy. J Clin Endocrinol Metab 1994; 79:1416–1423.

    Article  CAS  PubMed  Google Scholar 

  101. Lamberts S.W.J., de Herder W.W., van der Lely A.J., Hofland L.J. Imaging and medical management of clinically nonfunctioning pituitary tumors. Endocrinologist 1995; 5: 448–451.

    Google Scholar 

  102. Colao A., Lastoria S., Ferone D., Varrella P., Marzullo P., Pivonello R., Cerbone G., Acampa W., Salvatore M, Lombardi G. Pituitary uptake of In-111-DTPA-D-Phe1-0Ctreotide in the normal pituitary and in pituitary adenomas. J Endocrinol Invest 1999; 22: 176–183

    CAS  PubMed  Google Scholar 

  103. Borson-Chazot F., Houzard C., Ajzenberg C., Nocaudie M., Duet M., Mundler O., Marchandise X., Epelbaum J., Gomez De Alzaga M., Schafer J., Meyerhof W., Sassolas G., Warnet A. Somatostatin receptor imaging in somatotroph and non-functioning pituitary adenomas: correlation with hormonal and visual responses to octreotide. Clin Endocrinol 1997; 47: 589–598.

    Article  CAS  Google Scholar 

  104. Warnet A., Harris A.G., Renard E., Martin D., James-Deidier A., Chaumet-Riffaud P., and the French multicenter octreotide study group: A prospective multicenter trial of octreotide in 24 patients with visual defects caused by nonfunctioning and gonadotropin-secreting pituitary adenomas. Neurosurgery 1997;41:786–797.

    Article  CAS  PubMed  Google Scholar 

  105. Gasperi M., Petrini L., Pilosu R., Nardi M., Marcello A.A., Mastio F., Bartalena L., Martino E. Octreotide treatment does not affect the size of most non-functioning pituitary adenomas. J Endocrinol Invest 1993; 16:541–543.

    CAS  PubMed  Google Scholar 

  106. De Bruin T.W.A., Kwekkeboom D.J., van’t Verlaat J.W., Reubi J.C., Krenning E.P., Lamberts S.W., Croughs R.J. Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment, and studies in vitro. J Clin Endocrinol Metab. 1992;75.1310–1317.

    PubMed  Google Scholar 

  107. Klibanski A., Alexander J.M., Bikkal H.A., Hsu D.W., Swearingen B., Zervas N.T. Somatostatin regulation of glycoprotein hormone and free subunit secretion in clinically nonfunctioning and somatotroph adenomas in vitro. J Clin Endocrinol Metab 1991; 73: 1248–1255.

    CAS  PubMed  Google Scholar 

  108. Katznelson L., Oppenheim D.S., Coughlin J.F., Kliman B., Schoenfeld D.A., and Klibanski A. Chronic somatostatin analog administration in patients with a-subunit-secreting pituitary tumors. J Clin Endocrinol Metab 1992; 75: 1318–1325.

    Article  CAS  PubMed  Google Scholar 

  109. Andersen M., Bjerre P., Schrøder H.D., Edal A., Høilund-Carlsen P.F., Pedersen P.H., Hagen C. In vivo secretory potential and the effect of combination therapy with octreotide and cabergoline in patients with clinically non-functioning pituitary adenomas: Clin Endocrinol 2001; 54: 23–30

    Article  CAS  Google Scholar 

  110. Florio T., Thellung S., Arena S., Corsaro A., Spaziante R., Gussoni G., Acuto G., Giusti M., Giordano G., Schettini G. Somatostatin and its analog lanreotide inhibit the proliferation of dispersed human non-functioning pituitary adenoma cells in vitro. Eur J Endocrinol 1999:141:396–408

    Article  CAS  PubMed  Google Scholar 

  111. Saveanu A., Gunz G., Dufour H., Caron P., Fina F., Ouafik L., Culler M.D., Moreau J.P., Enjalbert A., Jaquet P. BIM-23244, a somatostatin receptor subtype 2-and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant GH-secreting adenomas. J Clin Endocrinol Metab 2001; 86:140–145.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Molecular and Clinical Endocrinology and Oncology, “Federico II” University of Naples, Naples, Italy

    Annamaria Colao

Authors
  1. Annamaria Colao
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Medicine, McGill University Heath Center, Montréal, Québec, Canada

    Coimbatore B. Srikant

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer Science + Business Media, Inc.

About this chapter

Cite this chapter

Colao, A. (2004). Somatostatin Analogs in the Treatment of Pituitary Tumors. In: Srikant, C.B. (eds) Somatostatin. Endocrine Updates, vol 24. Springer, Boston, MA. https://doi.org/10.1007/1-4020-8033-6_14

Download citation

  • DOI: https://doi.org/10.1007/1-4020-8033-6_14

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4020-7799-9

  • Online ISBN: 978-1-4020-8033-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation